Johnson & Johnson Alberta Health Innovation Partnership
Supporting Innovation and advancement of patient and health system outcomes
The Johnson & Johnson Alberta Health Innovation Partnership (JAHIP) is a $2.1 million collaboration between Alberta Economic Development and Trade, Janssen Inc. (part of the Pharmaceutical Companies of Johnson & Johnson) and the University Hospital Foundation.
The primary goal of JAHIP is to support innovation and advancement of patient and health system outcomes in specific life sciences areas.
JAHIP will begin by focusing on two distinct areas:
- the advancement of patient outcomes in prostate health;
- and the application of real-world evidence to improve the Alberta health system.
While these are the two current areas of focus, JAHIP allows for new areas of inquiry and the use of the fund to develop new innovation initiatives as needs and opportunities arise.
JAHIP builds on an existing partnership between Johnson & Johnson and Alberta Innovation and Advanced Education that began in 2010. Since then, the partnership has yielded four distinct life sciences initiatives: support for drug discovery efforts in Alberta; the formation of a co-managed fund to support diabetes research; a prostate cancer research fund; and a Real World Evidence initiative, of which the latter two are now part of JAHIP.
On June 7, 2016, JAHIP has awarded important financial support to four Alberta based prostate health research projects.
The selected fund recipients are:
Biofluid Biomarkers to Distinguish Indolent from Aggressive Prostate Cancer
- Principal Investigator: M. Eric Hyndman, University of Calgary
Prostate Proteases, Protease-Activated Receptors (PARs) & Prostate Cancer Progression
- Principal Investigator: Morley D. Hollenberg, University of Calgary
Predicting Prostate Cancer Metastasis Using a Biofluid Diagnostic Approach
- Principal Investigator: Dr. John Lewis, University of Alberta
Pilot Study of Changes in Androgen Receptor Splice Variant Status in Patients with Localized Prostate Cancer Undergoing Androgen Deprivation and Radiotherapy
- Principal Investigator: Harvey Quon, University of Calgary
Download the press release.